Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (FRA:FDY)

Germany flag Germany · Delayed Price · Currency is EUR
0.3240
+0.0060 (1.89%)
At close: Jan 9, 2026
6.58%
Market Cap884.71M
Revenue (ttm)85.20M
Net Income (ttm)-7.50M
Shares Outn/a
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume171
Open0.3240
Previous Close0.3180
Day's Range0.3240 - 0.3240
52-Week Range0.3040 - 0.3460
Betan/a
RSIn/a
Earnings DateMar 31, 2026

About FRA:FDY

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 925
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol FDY
Full Company Profile

Financial Performance

In 2024, FRA:FDY's revenue was 709.40 million, a decrease of -16.61% compared to the previous year's 850.73 million. Earnings were 39.73 million, a decrease of -63.42%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.